Four years of immunization with OM-85 BV to prevent respiratory infections in HIV+ patients

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1849-1851

  Capetti, Amedeo ^a   Cossu, Maria Vittoria ^a   Carenzi, Laura ^a   Rizzardini, Giuliano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

COPD; Four years; OM 85 BV; Recurrent sinusitis; Seasonal respiratory infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIUM LYSATE; CEFTIBUTEN; COTRIMOXAZOLE; LEVOFLOXACIN;

ACTIVE IMMUNIZATION; ARTICLE; BACTERIAL INFECTION; DRUG COST; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALAISE; NAUSEA; OTITIS; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

COPD; FOUR YEARS; OM-85 BV; RECURRENT SINUSITIS; SEASONAL RESPIRATORY INFECTIONS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CELL EXTRACTS; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS;

EID: 84884605058     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25104     Document Type: Article

References (9)

1. Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, et al. Association of Functional Impairment with Inflammation and Immune Activation in HIV Type 1-Infected Adults Receiving Effective Antiretroviral Therapy. J Infect Dis 2013; 208:249-59; PMID:23559466; http://dx.doi.org/10. 1093/infdis/jit147
2. Gingo MR, Balasubramani GK, Kingsley L, Rinaldo CR Jr., Alden CB, Detels R, et al. The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS One 2013; 8:e58812; PMID:23554932; http://dx.doi.org/10.1371/journal.pone.0058812
3. Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. Clin Chest Med 2007; 28:575-87, vi; PMID:17720045; http://dx.doi.org/10.1016/j.ccm.2007.06.004
4. Gurney TA, Lee KC, Murr AH. Contemporary issues in rhinosinusitis and HIV infection. Curr Opin Otolaryngol Head Neck Surg 2003; 11:45-8; PMID:14515102; http://dx.doi.org/10.1097/00020840-200302000-00010
5. Solèr M, Mütterlein R, Cozma G; Swiss-German OM-85 Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007; 74:26-32; PMID:16772707; http://dx.doi.org/10.1159/000093933
6. Sprenkle MD, Niewoehner DE, MacDonald R, Rutks I, Wilt TJ. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD 2005; 2:167-75; PMID:17136978; http://dx.doi.org/10.1081/COPD-200050674
7. Zhang M, Luan H, Zhang Q, Wang L, Lv YM, He F, et al. Prevention of infection in immunosuppressive patients with autoimmune nephrosis by using an immunostimulating bacterial lysate: Broncho-vaxom. Hum Vaccin Immunother 2012; 8; In Press; PMID:22922768; http://dx.doi.org/10.4161/hv.21874
8. Fortis AA, Lianou PE, Papavassilliou JT. Adherence of Staphylococcus aureus, Klebsiella pneumoniae and Candida albicans to human buccal epithelial cells, from healthy persons and HIV carriers, under the influence of Broncho Vaxom in vitro and ascorbic acid in vivo. APMIS 1998; 106:441-8; PMID:9637265; http://dx.doi.org/10.1111/j.1699-0463.1998.tb01369.x
9. Capetti A, Zucchi P, Landonio S, Terzi R, Argenteri B, Rizzardini G. Efficacy and tolerability of OM-85 BV in the prevention of seasonal respiratory infections in HIV-infected patients at high risk of recurrent events. Abs 12314, XVIII IAS Conference, Vienna, 18-23 July, 2010.